Citius Oncology (CTOR) Share-based Compensation (2023 - 2026)

Citius Oncology's Share-based Compensation history runs 4 years deep, the most recent figure standing at $3.5 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 68.86% year-over-year to $3.5 million; the TTM figure through Mar 2026 stood at $11.7 million (up 20.3% YoY), while the FY2025 annual figure was $8.1 million, up 8.24% from the prior year.
• Share-based Compensation was $3.5 million for Q1 2026 at Citius Oncology, down from $4.0 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $4.0 million in Q4 2025 to a low of $1.8 million in Q4 2024.
• Historically, Share-based Compensation has averaged $2.6 million across 4 years, with a median of $2.1 million in 2025.
• Biggest YoY gain for Share-based Compensation was 118.75% in 2025; the steepest drop was 46.09% in 2025.
• A 4-year view of Share-based Compensation shows it stood at $1.9 million in 2023, then retreated by 5.66% to $1.8 million in 2024, then surged by 118.75% to $4.0 million in 2025, then slipped by 10.85% to $3.5 million in 2026.
• The last three Share-based Compensation figures came in at $3.5 million (Q1 2026), $4.0 million (Q4 2025), and $2.1 million (Q3 2025), per Business Quant data.